Thus, the dual effect of LEENE in promoting the expression both eNOS and other proangiogenic genes, including that of growth factors (e.g., PGF and PDGF) and receptors (e.g., VEGFR2), would be highly desirable for ameliorating EC dysfunction and improving tissue perfusion in PAD. The gene discussed is NOS3; the disease is peripheral arterial disease.